Factor VIII gene therapy - Immune Response

Drug Profile

Factor VIII gene therapy - Immune Response

Alternative Names: GeneDrug™ - factor VIII

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Immune Response Corporation
  • Class Blood coagulation factors; Coagulants
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 25 Jun 2002 This product is still in active development
  • 26 Jul 1999 New profile
  • 26 Jul 1999 Preclinical development for Haemophilia A in USA (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top